

U.S.S.N.: 09/345,712

Filed: June 30, 1999

AMENDMENT AND RESPONSE TO OFFICE ACTION

cot
c2 sclerosis, [recessive dystrophic epidermolysis bullosa,] venous ulcers, molluscum contagious, seborrheic keratosis, and actinic keratosis comprising administering to the individual in need of treatment thereof an angiogenesis inhibitor wherein the angiogenesis inhibitor is selected from the group consisting of collagenase inhibitors, angiogenic fumagillin derivatives, 2,5-diaryltetrahydrofurans, aminophenylphosphonic acid compounds, 3-substituted oxindole derivatives, thalidomides, penicillamine and IL12 in an amount effective to inhibit angiogenesis.

c2 ✓ 6. (amended) The method of claim 5 wherein the angiogenesis inhibitor is [selected from the group consisting of collagenase inhibitors, endostatin, angiostatin, fumagillin derivatives-like] TNP-470[, 2,5-diaryltetrahydrofurans, aminophenylphosphonic acid compounds, 3-substituted oxindole derivatives, thalidomides, penicillamine and IL12].

c3 17. (twice amended) A method for inhibiting skin disorders selected from the group consisting of lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis comprising administering to the individual in need of treatment thereof an angiogenesis inhibitor in an amount effective to inhibit angiogenesis, wherein the angiogenesis inhibitor is selected from the group consisting of

tetracyclines inhibiting collagenase,

[endostatin,] and

a sulfated polysaccharide which inhibits angiogenesis.

Please add new claim 19.